Bristol Myers Squibb (CELG-RI) Capital Expenditures Growth (5y) (2014 - 2026)

Bristol Myers Squibb (CELG-RI) Capital Expenditures Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 14.94%
Dec 31, 2025 5.51%
Sep 30, 2025 15.90%
Jun 30, 2025 22.47%
Mar 31, 2025 6.93%
Dec 31, 2024 8.53%
Sep 30, 2024 11.26%
Jun 30, 2024 6.53%
Mar 31, 2024 6.84%
Dec 31, 2023 2.62%
Sep 30, 2023 8.83%
Jun 30, 2023 5.52%
Mar 31, 2023 3.07%
Dec 31, 2022 6.38%
Sep 30, 2022 -1.17%
Jun 30, 2022 1.86%
Mar 31, 2022 -2.76%
Dec 31, 2021 -2.91%
Sep 30, 2021 -4.56%
Jun 30, 2021 -4.26%